Navigation Links
Amgen Completes Acquisition of BioVex
Date:3/4/2011

lationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014  goBalto, Inc., the leading provider of ... a winner of Red Herring,s Top 100 Global ... North America award in 2013, marking its emergence as ... Red Herring,s Top 100 Global list has become ... and entrepreneurs. Red Herring editors were among the first ...
(Date:11/26/2014)...   Heska Corporation (NASDAQ: HSKA ) ... of advanced veterinary diagnostic and other specialty veterinary products ... will attend The Benchmark Company, LLC,s Micro Cap Discovery Conference ... held at The Palmer House Hilton, 17 E. Monroe Street, ... 2:30 p.m. Please email hska@haydenir.com or contact your ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 ... AZN ) today announced that AMAGINE-2 TM , a ... in more than 1,800 patients with moderate-to-severe plaque psoriasis, met ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg given ... each shown to be superior to Stelara on the primary ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/28/2014)... November 28, 2014 Dr. Paul Vitenas, one of ... a Glitter & Glow Holiday Event for those in the area ... at his practice. Glitter & Glow will take place on December ... new location in the heart of Houston at 4208 Richmond Ave. ... and hope that you will come and celebrate the season with ...
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... PreDiabetes Centers , a ... employees learn their risk for type 2 diabetes ... a local school in partnership with the American ... , As the Presenting Sponsor for the ... is co-hosting diabetes-prevention presentations at Austin-area companies with ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 More ... have now been filed in a New Jersey ... implants, Bernstein Liebhard LLP reports. , A ... County Superior Court reflects the filing of 2,160 ... hip stems, which were voluntarily recalled on July ...
(Date:11/28/2014)... 28, 2014 Patten Pecans, based in ... With those passions driving them, they've added a pecan ... tried other pecans oils, they've found this pecan ... be exceptionally flavorful, retaining the buttery pecan notes that ... nutritional benefits found in pecans nuts is found ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... older we get, the ,more difficulty we seem to have remembering ... each morning, but unless we park in the ,same space each ... whether we left the SUV in the second or fifth row. ... and will have forgotten ,their names before the handshake is over. ...
... - 13 May 2011 Elsevier, the world,s ... announced today that Syngene, India,s first contract research ... provide unlimited access to Reaxys for all Syngene ... competitiveness and productivity in the ever-expanding and highly ...
... , FRIDAY, May 13 (HealthDay News) -- A common ... the development of life-threatening heart arrhythmias (when the heart ... a new study. In pinpointing this gene, ... help doctors determine which patients are likely to benefit ...
... Lombard, IL, May 13, 2011 Dynamic chest ... compression has been well studied in events such ... not been studied during chiropractic manipulation. In a ... of Manipulative and Physiological Therapeutics , researchers quantified ...
... Ga. In a time of transition for rural ... them stay focused on their goals and avoid potential ... an ongoing University of Georgia study., The study, published ... of Community Psychology, is part of a broader ...
... New data offer hints to why Parkinson,s disease so ... say researchers at Washington University School of Medicine in ... communications including the signals that control movement. As Parkinson,s ... problems moving and other symptoms. The new research ...
Cached Medicine News:Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Gene Variant Linked to Sudden Cardiac Death Risk in Blacks 2Health News:Chiropractic manipulation results in little or no risk of chest injury 2Health News:Study finds youth-mentor relationships particularly helpful for those experiencing hardship 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 2Health News:Disruption of nerve cell supply chain may contribute to Parkinson's 3
5 inch (12.7 cm), 2 x 5 mm blade....
Nicati foreign body spud....
In reversible handle for removing foreign bodies....
... Focus Night & Day soft contact ... to protect the cornea and to relieve ... or chronic ocular pathologies such as bullous ... corneal dystrophies as well as post-surgical conditions ...
Medicine Products: